FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Re...
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.| Eli Lilly and Company
